S Korkmaz1, H Korkmaz2. 1. Trakya University Faculty of Medicine, Department of Dermatology, Edirne, Turkey. 2. Edirne Sultan 1. Murat State Hospital, Department of Endocrinology and Metabolic Disease, Edirne, Turkey.
Abstract
BACKGROUND: An increase in the incidence of metabolic syndrome (MetS) has been identified in patients with psoriasis. OBJECTIVES: To evaluate the role of changes in expression of apoptosis activators [B-cell lymphoma (Bcl)-2-like protein 4 (BAX), cytochrome c (cytC) and caspase-3 (CASP3)] and apoptosis inhibitors [Bcl-2, survivin, cyclin D1 (CCND1), superoxide dismutase (SOD), catalase 3 (CAT), glutathione synthetase (GS), heat shock protein (Hsp)27, Hsp60, Hsp70 and Hsp90] on development of MetS in patients with psoriasis vulgaris. METHODS: Fifty patients with psoriasis were enrolled; 25 had MetS. Twenty-five healthy people and 25 people with only MetS were included as a control group. Serum fasting blood glucose, urea, creatinine, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, thyroid-stimulating hormone, fraction of thyroxine, fasting insulin and highly sensitive C-reactive protein levels were measured. Expression of BAX, cytC, CASP3, Bcl-2, survivin, CCND1, SOD, CAT, GS, and Hsp27, Hsp60, Hsp70 and Hsp90 were measured in peripheral blood. Clinical activation of patients with psoriasis was calculated using Psoriasis Area and Severity Index scores. RESULTS: In patients with MetS there was an increase in expression of genes for cytC, survivin and Hsp27, Hsp60 and Hsp90, and a decrease in expression of CCND1. Furthermore, expression levels of CCND1 were identified to be an independent risk factor for MetS development in patients with psoriasis. CONCLUSIONS: The increase in expression of survivin and Hsp27, Hsp60 and Hsp90, and the decrease in CCND1 expression may be important mechanisms in the development of MetS in patients with psoriasis.
BACKGROUND: An increase in the incidence of metabolic syndrome (MetS) has been identified in patients with psoriasis. OBJECTIVES: To evaluate the role of changes in expression of apoptosis activators [B-cell lymphoma (Bcl)-2-like protein 4 (BAX), cytochrome c (cytC) and caspase-3 (CASP3)] and apoptosis inhibitors [Bcl-2, survivin, cyclin D1 (CCND1), superoxide dismutase (SOD), catalase 3 (CAT), glutathione synthetase (GS), heat shock protein (Hsp)27, Hsp60, Hsp70 and Hsp90] on development of MetS in patients with psoriasis vulgaris. METHODS: Fifty patients with psoriasis were enrolled; 25 had MetS. Twenty-five healthy people and 25 people with only MetS were included as a control group. Serum fasting blood glucose, urea, creatinine, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, thyroid-stimulating hormone, fraction of thyroxine, fasting insulin and highly sensitive C-reactive protein levels were measured. Expression of BAX, cytC, CASP3, Bcl-2, survivin, CCND1, SOD, CAT, GS, and Hsp27, Hsp60, Hsp70 and Hsp90 were measured in peripheral blood. Clinical activation of patients with psoriasis was calculated using Psoriasis Area and Severity Index scores. RESULTS: In patients with MetS there was an increase in expression of genes for cytC, survivin and Hsp27, Hsp60 and Hsp90, and a decrease in expression of CCND1. Furthermore, expression levels of CCND1 were identified to be an independent risk factor for MetS development in patients with psoriasis. CONCLUSIONS: The increase in expression of survivin and Hsp27, Hsp60 and Hsp90, and the decrease in CCND1 expression may be important mechanisms in the development of MetS in patients with psoriasis.